Blonanserin

Blonanserin

Systematic (IUPAC) name
2-(4-ethylpiperazin-1-yl)-4-(4-fluorophenyl)-5,6,7,8,9,10-hexahydrocycloocta[b]pyridine
Clinical data
Pregnancy cat.	?
Legal status	℞ Prescription only
Routes	Oral
Identifiers
CAS number	132810-10-7
ATC code	None
PubChem	CID 125564
ChemSpider	111697
UNII	AQ316B4F8C Y
KEGG	D01176
Chemical data
Formula	C23H30FN3
Mol. mass	367.50 g/mol
SMILES	eMolecules & PubChem

Blonanserin (Lonasen) is a relatively new atypical antipsychotic commercialized by Dainippon Sumitomo Pharma in Japan and Korea for the treatment of schizophrenia. Relative to many other antipsychotics, blonanserin has an improved tolerability profile, lacking side effects such as extrapyramidal symptoms and excessive sedation and hypotension.

Blonanserin acts as a mixed 5-HT₂ (K_i = 3.98 nM) and D₂ receptor (K_i = 14.8 nM) antagonist. It also exerts some blockade of α₁-adrenergic receptors (K_i = 56.3 nM) and has low affinity for the sigma receptor (IC₅₀ = 286 nM). Blonanserin lacks significant affinity for numerous other sites including 5-HT₁, 5-HT₃, D₁, α₂-adrenergic, β-adrenergic, H₁, mACh, and the monoamine transporters.

See also

• Atypical antipsychotic